Diagnostic Accuracy of Risk Malignancy Index (RMI) in Diagnosing Ovarian Carcinoma, Confirming the Diagnosis by Histopathology

Anam Manzoor Alam; Syed Salman  Ali; Javaria  Ahsan; Syed Ali  Ghawas; Urooj  Alam; Mustajab  Alam

doi:10.51253/pafmj.v75i5.11438

Authors

Anam Manzoor Alam Department of Obstetrics and Gynecology, Combined Military Hospital Skardu/National University of Medical Sciences (NUMS) Pakistan
Syed Salman Ali Department of Histopathology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Javaria Ahsan Department of Histopathology, Combined Military Hospital Kharian/National University of Medical Sciences (NUMS) Pakistan
Syed Ali Ghawas Department of Medicine, Combined Military Hospital Skardu/National University of Medical Sciences (NUMS) Pakistan
Urooj Alam Department of Medicine, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Mustajab Alam Department of Medicine, Combined Military Hospital Skardu/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i5.11438

Keywords:

Histopathology, Ovarian Carcinoma, Risk Malignancy Index

Abstract

Objective: To determine the diagnostic accuracy of risk malignancy index (RMI) in early diagnosis of ovarian carcinoma, keeping histopathology as gold standard.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Obstetrics and Gynecology, Combined Military Hospital, Skardu Pakistan, from Nov 2022 to Nov 2023.

Methodology: A total of 106 patients aged 20-60 years with presence of ovarian mass on ultrasonography were included in the study. Risk malignancy index was calculated, and presence or absence of ovarian carcinoma was noted. All patients then underwent surgery, and specimen was sent for histopathology. RMI findings were compared with histopathology report.

Results: RMI supported the diagnosis of ovarian carcinoma in 62(58.49%) patients. Histopathology findings confirmed ovarian cancer in 64(60.38%) cases. In RMI positive patients, 57 were True Positive and 05 were False Positive. Among the 44 RMI negative patients, 07 were False Negative whereas 37 were True Negative. Overall sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of risk malignancy index (RMI) in early diagnosis of ovarian carcinoma, confirming the diagnosis by histopathology was 89.06%, 88.10%, 91.94%, 84.08% and 88.68% respectively.

Conclusion: This study concluded that diagnostic accuracy of risk malignancy index (RMI) in early diagnosis of ovarian carcinoma is significantly high.

Downloads

Download data is not yet available.

References

Liu J, Tang W, Sang L, Dai X, Wei D, Luo Y, et al. Milk, yogurt, and lactose intake and ovarian cancer risk: a meta-analysis. Nutr Cancer 2015; 67(1): 68-72.

https://doi.org/10.3389%2Ffsurg.2022.877857

2. Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer 2015; 22(6): 339-363.

https://doi.org/10.1530/erc-14-0550

3. Suh-Burgmann E, Kinney W. The value of ultrasound monitoring of adnexal masses for early detection of ovarian cancer. Front Oncol 2016; 6: 25.

https://doi.org/10.3389%2Ffonc.2016.00025

4. Khaskheli M, Baloch S, Baloch AS. Gynecological malignancies: a continuing threat in the developing world. J Gynecol Surg 2010; 26(2): 121-125.

https://doi.org/10.12669%2Fpjms.321.8663

5. Karimi-Zarchi M, Mojaver SP, Rouhi M, Hekmatimoghaddam SH, Moghaddam RN, Yazdian-Anari P, et al. Diagnostic value of the risk of malignancy index (RMI) for detection of pelvic malignancies compared with pathology. Electron Physician 2015; 7(7): 1505–1510. https://doi.org/10.19082%2F1505

6. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117(6): 1289-1297.

https://doi.org/10.1097/aog.0b013e31821b5118

7. Dogheim OY, Hamid AEMA, Barakat MS, Eid M, El-Sayed SM. Role of novel magnetic resonance imaging sequences in characterization of ovarian masses. Egyptian J Radiol Nuclear Med 2014; 45: 237–251.

http://dx.doi.org/10.1016/j.ejrnm.2013.11.008

8. Smorgick N, Maymon R. Assessment of adnexal masses using ultrasound: a practical review. Intl J Women’s Health 2014; 6: 857–863. https://doi.org/10.2147/ijwh.s47075

9. Dwivedi A, Jain S, Shukla R, Jain M, Srivastava A, Verma A. MRI is a state of art imaging modality in characterization of indeterminate adnexal masses. J Biomed Sci Engine 2013; 6309-6913. http://dx.doi.org/10.4236/jbise.2013.63A039

10. Al-Musalhi K, Al-Kindi M, Ramadhan F, Al-Rawahi T, Al-Hatali K, Mula-Abed WA. Validity of cancer antigen-125 (CA-125) and risk of malignancy index (RMI) in the diagnosis of ovarian cancer. Oman Med J 2015; 30(6): 428–434.

https://doi.org/10.5001/omj.2015.85

11. Aziz AB, Najmi N. Is risk malignancy index a useful tool for predicting malignant ovarian masses in developing countries. Obstet Gynecol Int 2015; 1-5.

https://doi.org/10.1155/2015/951256

12. Terzic M, Dotlic J, Likic I, Brndusic N, Pilic I, Ladjevic N, et al. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Taiwanese J Obstet Gynecol 2013; 52: 253-257.

https://doi.org/10.1016/j.tjog.2013.04.017

13. Yelikar KA, Deshpande SS, Nanaware SS, Pagare SB. Evaluation of the validity of risk malignancy index in clinically diagnosed ovarian masses and to compare it with the validity of individual constituent parameter of risk malignancy index. Int J Reprod Contracept Obstet Gynecol 2016; 5: 460-464.

http://dx.doi.org/10.18203/2320-1770.ijrcog20160391

14. Javdekar R, Maitra N. Risk of malignancy index (RMI) in evaluation of Adnexal mass. J Obstet Gynaecol India 2015; 65: 117-121.

https://doi.org/10.1007/s13224-014-0609-1

15. Irshad F, Irshad M, Naz M. Accuracy of Risk of Malignancy Index in preoperative diagnosis of ovarian malignancy in post menopausal patients. Rawal Med J 2013; 38: 266-270.

16. Van Trappen PO, Rufford BD, Mills TD, Sohaib SA, Webb JA, Sahdev A, et al. Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer 2007; 17(1): 61-67.

https://doi.org/10.1111/j.1525-1438.2006.00753.x

17. Van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, et al. Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. Gynecologic Oncol 2010; 116(3): 384–388.

https://doi.org/10.1016/j.ygyno.2009.11.014

18. Abdulrahman GP, McKnight L, Singh KL. The risk of malignancy index (RMI) in women with adnexal masses in Wales. Taiwan J Obstet Gynecol 2014; 53: 376-381.

https://doi.org/10.1016/j.tjog.2014.05.002

19. Manjunath A, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001; 81(2): 225–229.

20. Obeidat B, Amarin Z, Latimer J, Crawford R. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynecol Obstet 2004; 85(3): 255–258.

https://doi.org/10.1016/j.ijgo.2003.10.009

21. Mohammed ABF, Ahuga VK, Taha M. Validation of the Risk of Malignancy Index in primary evaluation of ovarian masses. Middle East Fertil Soc J 2014; 19(4): 324–328.

http://doi.org/10.1016/j.mefs.2014.03.003

22. Engelen MJA, Bongaerts AHH, Sluiter WJ, de Haan HH, Bogchelman DH, TenVergert EM, et al: Distinguishing benign and malignant pelvic masses: The value of different diagnostic methods in everyday clinical practice. European J Obstet Gynecol Reproductive Biol 2008; 136(1): 94-101.

https://doi.org/10.1016/j.ejogrb.2006.10.004

23. Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 2006; 16(1): 30–34.

https://doi.org/10.1111/j.1525-1438.2006.00468.x

24. Royal College of obstetrician and gynaecologists (RCOG). investigation and management of ovarian cyst in a postmenopausal woman. London: Royal College of obstetrician and gynaecologists, (2003) Guideline No. 34. Royal college obstet gynecol 2003: 34.